Ayisha Sharma
Reporter
Ayisha joined Scrip in 2021 after working as an investigative reporter at GlobalData's pharmaceutical news platform, BioPharm Insight, where she covered the beats of hematology, oncology and rare diseases. She holds an MA in Philosophy from University College London and an NCTJ diploma in multimedia journalism. Ayisha is interested in psychiatric disorders and drug development focused on the microbiome.
Latest From Ayisha Sharma
Lundbeck And Axsome Rival Candidate Data Raise Prospects For First Alzheimer’s Agitation Approvals
The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.
Executives On The Move: AbbVie, FSD Pharma and More
Recent executive changes in the industry include C-suite changes at AbbVie and Pharnext. Meanwhile, new directors were appointed at Zydus Lifesciences and FSD Pharma.
Acousia To Refresh Stagnant Hearing Loss Space With New Potassium Channel Approach
The German biotech plans to prevent chemotherapy-induced hearing loss and treat chronic hearing loss by targeting a potassium channel in the ear’s sensory hair cells as it tackles a widespread but side-lined area.
Megadeal Ahead? Horizon In Takeover Talks With Big Pharma For $20bn+ Deal
The Irish firm revealed it was in early conversations with Amgen, J&J and Sanofi regarding a possible takeover, with some experts touting the potential for a deal far surpassing the $20bn mark.
C4XD Inks Third Major Deal, This Time With AZ For Oral COPD Drug
The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.
Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.